Bluebird Bio and Celgene Partner to Advance bb2121, Potential Multiple Myeloma CAR T-cell Therapy
News
The investigational therapy bb2121, a possible treatment for relapsed or refractory multiple myeloma patients, is advancing in clinical testing under a recently announced partnership between bluebird bio and Celgene. The companies ... Read more